Introduction
Hemophilia B is a sex-linked hereditary bleeding disorder related to a plasma deficiency in functional blood coagulation Factor IX (1, 2) . Plasma deficiencies in functional Factor IX result when there is a defect in the expression of the Factor IX gene or when the product of gene expression is structurally abnormal. Hemophilia B has been subclassified according to the plasma level of Factor IX antigen or cross-reacting material
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Received for publication 2 April 1984 and in revised form 19 September 1984. (CRM)' to antisera specific for Factor IX (3) . In previous studies we investigated the structure/function of abnormal Factor IX isolated from the plasma of CRM' hemophilia B patients, i.e., patients with essentially normal plasma Factor IX antigen levels but significantly decreased Factor IX clotting activity (3) . Factor IXChapel Hill, isolated from the plasma of a CRM' hemophilia B patient with a clinically mild bleeding tendency, has been studied in some detail (4) (5) (6) . Factor IXChapel Hill is activated by incubation with Factor XIa/calcium, but the rate of activation is somewhat slower than the rate of activation of normal Factor IX (5) . In addition, the apparent clotting activity of activated Factor IXChapel Hill is only 20% of the clotting activity of activated normal Factor IX.2 Activation of Factor IXChapel Hill was associated with the cleavage of only one (Argl 80-Val 181) of the two sites cleaved by Factor XIa/ calcium during the activation of normal Factor IX (Argl45-Ala146, Argl80-Vall81) (5) . Recently we reported that the structural defect in Factor IXChhapel Hill is in the substitution of histidine for arginine at position 145 in the primary structure (6) , which would appear to explain the inability of Factor XIa/ calcium to cleave the protein at this site.
The cleavage/activation of bovine and human Factor IX by a protease present in Russell's viper venom (RW-X) has been reported (7, 8) . Cleavage of Factor IX by RVV-X/calcium occurs predominantly at one site (human Factor IX, Arg180-Vall8 1; bovine Factor IX, Arg18 1-Val 182) to produce Factor IXaa (M, = 57,000). Factor IXaa is composed of two polypeptide chains, which are held together by disulfide bonds. The specific clotting activity of bovine Factor IXaa has been reported to be -twofold lower than the clotting activity of bovine Factor IXafi (7) . Factor IXafi is also composed of two polypeptide chains held together by disulfide bonds, but the additional cleavage of the protein at a second site (human Factor IX, Argl45-Alal46; bovine Factor IX, Arg146-Alal47) appears to release an activation peptide (Mr = 11,000), with a 1. Abbreviations used in this paper: CRM, cross-reacting material; HPLC, high-performance liquid chromatography; kA;. apparent first order rate constant for Factor X activation by activated Factor IX; PEG, polyethylene glycol; RVV, Russel's viper venom; RVV-X, a protease present in Russell's viper venom; TEA, triethanolamine; TosGlyProArgNaN, Na-p-tosyl-glycyl-L-prolyl-L-arginine-p-nitroanilide. Factors IX and X (as well as prothrombin), which coelute from the DEAE-cellulose column, were separated from one another by dextran sulfate-agarose column chromatography as previously described (12) . Effluent fractions from the dextran sulfate-agarose column containing Factors IX and X were separately pooled and concentrated by adsorption to and elution from a 1.0-cc bed volume DEAE-cellulose column. The preparations of Factor IX (200 U/mg) and Factor X (100 U/mg) were homogeneous as judged by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (13 Human antithrombin III was isolated from barium citrate-adsorbed plasma by heparin-agarose affinity chromatography essentially as described previously (14) . The preparation was judged to be homogeneous by SDS-polyacrylamide gel electrophoresis (13) . Antithrombin III concentration was determined spectrophotometrically at 280 nm by means of an extinction coefficient value of 0.6 ml mg-' cm-' (14) .
When an M, of 65,000 was used (14) , 1 mol of purified antithrombin III was required to inactivate I mol of human a-thrombin in the presence or absence of heparin (15) .
Human Factor XIa was partially purified from Celite (Celite 545; Johns-Manville Sales Corp., Denver, CO) activated human plasma as described previously (5) . Factor XIa and RVV3 were covalently coupled to agarose (Sepharose 4B) by the procedure described previously (16) .
Measurement of activated Factor IX by plasma clotting activity. The clotting activities of solutions containing activated Factor IX were determined by the addition of 0.075-ml sample to a fibrometer cup containing 0.075 ml of nonactivated Factor IX deficient plasma and 0.075 ml Thrombofax. After the mixture was warmed to 370C, 0.075 ml of 25 mM calcium chloride was added and the fibrometer was started. The clotting times of normal Factor IXa# solutions, ranging in concentration from 2.5 to 250 nM (0.01125 to 11.25 Mg/ml), were used to construct a standard curve. The clotting time of a given activated Factor-IX solution was converted to the equivalent normal Factor IXaj# concentration from the standard curve. Therefore, activated Factor IX concentrations, determined by clotting activity, are expressed in micrograms or moles of normal Factor IXaj6 per unit volume.
Measurement ofactivated Factor IX by Factor X/polylysine activity. Activated Factor IX was added to a solution containing 400 nM Factor X, 50 nM polylysine, 0.3 mM TosGlyProArgNaN, 0.1 M TEA (pH 8.0), 0.1 M NaCl, and 0.1% PEG. After the solution was mixed it was transferred to a 1.0-cm path length cuvette, which was then placed in a Beckman Acta CIII spectrophotometer (Beckman Instruments, Inc., Palo Alto, CA). The change in absorbance at 400 nm was measured as a function of incubation time at room temperature. The rate of change in absorbance per minute of incubation time (dcddt) increased linearly with incubation time (t) as described by the following first order rate equation:
where k," is the apparent first order rate constant for Factor X activation by activated Factor IX, and C is the rate of change in A.4w
due to the hydrolysis of TosGlyProArgNaN by Factor Xa Under the experimental conditions described above, the value of C was 1.374 X 10' (ODU/min)/M Factor Xa. This value was determined by the addition of a known amount of Factor Xa (RVV-agarose/calcium activated Factor X, active site titrated by the use of antithrombin III)
to the buffer/polylysine/TosGlyProArgNaN solution and measurement of the initial rate of increase in A.4o.
The absorbance (Am4m) at any given incubation time was described by the integrated form of Eq. 1. HCl (pH 7.0), 0.5 M NaCl, and the flow rate was 0.5 ml/min. In a typical experiment, 0.2-ml sample containing 0.225 mg/ml of protein was injected and a 5.5-ml fraction was collected before the collection of 0. 12-ml fractions. Essentially 100% of the protein, as determined by activity assays, was recovered in all experiments. The separation of Factor IXafi from Factor IXaa (and Factor IX) was somewhat better than expected strictly on the basis of the molecular weight differences. The elution volume of Factor IXaa (7.3 ml) corresponded to an apparent molecular weight of 80,000 (actual molecular weight, 57,000), whereas the elution volume of Factor IXapi (8.3 ml) corresponded to an apparent molecular weight of 45,000, which is the actual molecular weight of Factor IXaft.
Results
Factor X activation by activated Factor IX in the presence of polylysine. Factor IXapi, prepared by incubation of normal Factor IX with Factor XIa-agarose/calcium, was added to a solution containing Factor X, polylysine, and TosGlyProArgNaN, and the absorbance of the solution at 400 nm was followed spectrophotometrically over a 10-min incubation time. A similar experiment was run in which buffer was added instead of Factor IXafl. In the presence of Factor IXafl, the absorbance increased nonlinearly with incubation time, whereas in the absence of Factor IXap, the absorbance increased linearly. These results are shown in Fig. 1 . The rate of change in absorbance (AA4A) per minute of incubation time in the presence of Factor IXaM was plotted as a function of incubation time. As shown in the inset in Fig. 1 , the AA400 per minute values increased linearly with incubation time which, according to Eq. 1, indicated that the activation of Factor X by Factor IXa,# in the presence of polylysine followed first order kinetics over the 10-min incubation. From the slope of the line (Fig.   1, inset) , kob was calculated according to Eq. 1 to be equal to 0.30 nM Factor Xa/min. The absorbance values at t = 10 min for both experiments (A400 = 0.365, A~w = 0.135) were used in Eq. 3 to calculate the kob; 0.30 nM Factor Xa/min. It is apparent that either method of calculation gives equivalent values for kb,.
The linear increase in absorbance observed in the absence of Factor IXa(# suggested that trace amounts of Factor Xa were present in the Factor X preparation. For the experiment shown in Fig. 1 , the rate of increase in absorbance was 0.0135 ODU/min, which corresponds to a Factor Xa concentration of -1.0 nM. Since the Factor X concentration in the experiment was 400 nM, only 0.25% of the preparation appeared to be activated. The amount of Factor Xa present in the Factor X prepartion was variable, however, and appeared to increase with storage at 4°C. Since the Factor X preparation, treated with diisopropylfluorophosphate immediately after isolation, was initially devoid of amidolytic activity, it appeared that a protease able to activate Factor X in the absence of calcium was a contaminant of the preparation. The protease is not susceptible to inhibition by diisopropylfluorophosphate or able to hydrolyze TosGlyProArgNaN. Storage of the Factor X preparation at -70°C greatly decreased Factor X activation; therefore, freshly thawed Factor X solutions were used in all subsequent experiments. A control, however, was run for each assay series.
The rates of activation of Factor X in the presence of polylysine by Factor IXaj and activated factor IXh, Hill were not measurably different. Solutions containing approximately equal concentrations of both enzymes were titrated with antithrombin III to determine the active site concentrations. As shown in Fig. 2 Figure 4 . High-performance size exclusion chromatography of RVV-agarose-activated normal Factor IX. Factor IX was incubated with RVV-agarose/calcium as described in the legend to Fig. 3 . At timed intervals, 0.2-ml samples were removed and chromatographed by HPLC as described in Methods. After a 5.5-ml fraction was collected (not shown), 0. 12-ml fractions were collected and assayed for activated Factor IX by Factor X/polylysine activity (-) and by clotting activity (-) as described in Methods.
all of the Factor X/polylysine activity was present in a single peak. By 4 h, however, a second peak of Factor X/polylysine activity could be distinguished, which, by 6 h of incubation, was quite pronounced. The ratio of clotting activity to Factor X/polylysine activity in the first peak was 0.17, whereas the ratio in the second peak was essentially 1.0. These results indicate that the increase in clotting activity observed with prolonged incubation of Factor IX with RVV-agarose/calcium (Fig. 3) is associated with the conversion of Factor IXaa to a lower apparent molecular weight form of Factor IX, which is as active as Factor IXa,3 in the clotting and Factor X/ polylysine activity assays.
The second peak of Factor X/polylysine activity obtained with RVV-agarose/calcium activated Factor IX (Fig. 4) eluted from the HPLC column in the same volume as the Factor X/ polylysine activity in Factor XIa-agarose/calcium activated Factor IX, i.e., Factor IXafl. These results are shown in Fig.   5 . Samples of RVV-agarose/calcium activated Factor IX were subjected to SDS-polyacrylamide gel electrophoresis under nonreducing conditions. Most of the RVV-agarose/calcium activated Factor IX migrated at the same rate as unactivated Factor IX, and a small amount of the protein migrated at the same rate as Factor IXa# (not shown). A (8) .
The concentrations of various activated Factor IX solutions were determined by both Factor X/polylysine activity and clotting activity. The ratio between the concentrations determined by clotting activity and Factor X/polylysine activity was defined as the relative activity of the activated Factor IX preparation. The Activation of human Factor IX by incubation with RVVagarose/calcium has been shown to be associated with the rapid cleavage of the Argl80-Vall81 peptide bond, but additional cleavage has been observed (8) . In the present study we have shown that two enzyme forms of Factor IXa are produced by RVV-agarose/calcium cleavage of Factor IX. The predominant enzyme produced was Factor IXaa whereas the second enzyme was indistinguishable from Factor IXaMO, as suggested previously (8) . In our initial attempts to prepare Factor IXaa we used much larger amounts of RVV-agarose than in the present report. Although this greatly decreased the incubation time required to activate the Factor IX, we found that the clotting activity rapidly approached the clotting activity expected for Factor IXaf, as reported by DiScipio and co-workers (8 Hill results in a significant bleeding diathesis.
The present study has shown that activated Factor IXChapel Hill, Factor IXaa, and Factor IXafi activate Factor X at similar rates in the presence of polylysine. This observation is interesting in that it indicates that there are conditions under which the three enzymes are essentially equally active. The mechanism of action of polylysine in accelerating the rate of Factor X activation by activated Factor IX is not known, however, and it is difficult to compare rates of Factor X activation in the presence of polylysine with rates of activation observed in the presence of cofactors (calcium, phospholipid, Factor VIlla). In an earlier study we observed a rate of Factor X activation of 20.5 mol Factor Xa/min per mol Factor IXa# in the presence of 5 U/ml Factor VI1a and optimal levels of calcium and phospholipid (19) . This rate is obviously much greater ('600-fold) than the rate of Factor X activation in the presence of polylysine observed in the present study. Although this suggests that polylysine is not as effective as calcium, phospholipid, Factor VIIIa in promoting Factor X activation, the conditions for Factor X activation in the presence of polylysine used in the present study may not have been optimal. In any event, the similar rates of Factor X activation in the presence of polylysine by the three enzymes studied herein suggests that the enzymes are structurally/functionally similar with respect to interactions with Factor X and polylysine, whereas cofactor interactions, as measured by relative clotting activities, appear to differ significantly. Furthermore, these results appear to indicate that the active site regions of the three enzymes are similar with respect to the Factor X binding domain and the active sites residues required for the cleavage of Factor X. Determination of the mechanism of action of polylysine may reveal structural properties of activated Factor IX that are important for cofactor (calcium, phospholipid, Factor VIIIa) interactions and a better understanding of the structure/function of Factor IX.
